A number of other equities analysts have also commented on MNK. Oppenheimer reiterated a market perform rating on shares of Mallinckrodt in a report on Wednesday, November 22nd. UBS lowered shares of Mallinckrodt from a buy rating to a neutral rating and cut their price objective for the stock from $70.00 to $24.00 in a report on Sunday, November 26th. Barclays set a $23.00 price objective on shares of Mallinckrodt and gave the stock a hold rating in a report on Tuesday, December 12th. Canaccord Genuity set a $24.00 target price on shares of Mallinckrodt and gave the company a hold rating in a research note on Tuesday, December 26th. Finally, Goldman Sachs restated a hold rating on shares of Mallinckrodt in a research note on Tuesday, December 26th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. Mallinckrodt has an average rating of Hold and a consensus price target of $38.50.
Mallinckrodt stock opened at $16.09 on Friday. Mallinckrodt has a 1-year low of $15.27 and a 1-year high of $49.12. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.18 and a quick ratio of 1.85. The company has a market cap of $1,389.38, a price-to-earnings ratio of 2.14, a price-to-earnings-growth ratio of 0.34 and a beta of 1.06.
Mallinckrodt (NYSE:MNK) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.29. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. The firm had revenue of $792.30 million for the quarter, compared to analyst estimates of $769.91 million. During the same quarter in the previous year, the business posted $1.91 EPS. The firm’s revenue was down 4.5% compared to the same quarter last year. equities analysts expect that Mallinckrodt will post 6.22 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in MNK. Shelton Capital Management bought a new position in Mallinckrodt in the 3rd quarter worth about $205,000. State of Alaska Department of Revenue bought a new position in Mallinckrodt in the 4th quarter worth about $129,000. Cubist Systematic Strategies LLC grew its position in Mallinckrodt by 748.1% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 7,989 shares of the company’s stock worth $299,000 after purchasing an additional 7,047 shares during the last quarter. Pinnacle Associates Ltd. grew its position in Mallinckrodt by 69.8% in the 3rd quarter. Pinnacle Associates Ltd. now owns 8,025 shares of the company’s stock worth $300,000 after purchasing an additional 3,300 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. bought a new position in Mallinckrodt in the 3rd quarter worth about $305,000. 97.38% of the stock is owned by institutional investors and hedge funds.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.